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REPLY 
To the Editor: 
Drs. Glinski and Jablonska's letter illustrates the confusion that 
exists concerning the effect of methoxsalen photochemotherapy on 
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lymphocyte function in vivo. I will not add to this confus ion in t his 
forum; however, I would like to emphasize the fo llowing points: 
l. Ou1· study was designed to ascertain any defects in T -lymphocyte 
function in psoriatics who had undergone long-term. methoxsalen pho-
tochemotherapy . OuT experiments were not designed to measm e any 
short-term accuLe effects that the therapy migh t induce. We at tempted 
to see if long-term methoxsalen phoLochemotherapy indu ces lympho-
cyte abnormali ties in vivo. 
2. Our study makes no attempt to compare T -ly mphocyte function 
between untreated-psoriatic patients and normal healthy ind ividua ls. 
Hence, this poin t was not discussed in our paper. 
3. Drs. Glinski and Jablonski sLate that s ince t he patie nts in our 
paper were on main tenance therapy and free of active psoriatic lesions, 
they would have expected normal ce ll mediated immunity. This rea-
soning excludes the possibili ty Lhat long-te rm methoxsalen photochem-
otherapy could induce systemic abnormalities. It would be presump-
tuous to assume that cell mediated immunity hou ld be normal in these 
patients s imply because they have inactive disease. 
4. It should be noted that our paper was in press at the t ime Drs. 
Glinski and J a blonska's paper apperu·ed in print; therefore, we had no 
opportu nity to consider their resu lts in the writing of our paper. 
I believe that in the ligh t of documented evidence s howing a dramatic 
increase in basal and squa mous cell cru·cinoma in psoriatic patients 
undergoing methoxsalen phot.ochemotherapy, t he possibility exists that 
long-term methoxsalen photochemotherapy could lead to syst.e•n ic 
abnormalities. 
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